2025 Competitive Landscape Analysis Report for the MedTech Healthcare IT Sector, Highlighting Medtronic, Abbott, Johnson & Johnson Services Inc., Siemens Healthineers AG, Oracle Health, and Optum | Intellectia.AI
2025 Competitive Landscape Analysis Report for the MedTech Healthcare IT Sector, Highlighting Medtronic, Abbott, Johnson & Johnson Services Inc., Siemens Healthineers AG, Oracle Health, and Optum
Written by Emily J. Thompson, Senior Investment Analyst
Market Overview: The report analyzes the global MedTech and healthcare IT market, focusing on leading companies, innovative technologies, and regulatory updates in the U.S., Europe, and Japan.
Industry Scope: It encompasses medical devices, in vitro diagnostics (IVD), and healthcare IT, detailing products like surgical gloves, insulin pumps, and electronic health records.
Competitive Landscape: The report includes a market share analysis of key players such as Medtronic and Johnson & Johnson, along with insights into R&D investments and emerging technologies like blockchain and nanotechnology.
Regulatory Insights: An update on the regulatory frameworks across different regions is provided, highlighting the impact of macroeconomic factors and geopolitical events on the MedTech healthcare IT industry.
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 108.610
Low
136.00
Averages
148.11
High
169.00
Current: 108.610
Low
136.00
Averages
148.11
High
169.00
Wells Fargo
Larry Biegelsen
Overweight
downgrade
$146 -> $122
2026-01-23
New
Reason
Wells Fargo
Larry Biegelsen
Price Target
$146 -> $122
AI Analysis
2026-01-23
New
downgrade
Overweight
Reason
Wells Fargo analyst Larry Biegelsen lowered the firm's price target on Abbott to $122 from $146 and keeps an Overweight rating on the shares. The firm notes the company reported a Q4 sales miss and in-line EPS on transitory headwinds. 2026 organic sales growth guidance of 6.5%-7.5% is below prior consensus due to Nutrition headwinds persisting into the first half of 2026. EPS guide was in line, Wells adds.
Citi
Joanne Wuensch
Buy
downgrade
$155 -> $140
2026-01-23
New
Reason
Citi
Joanne Wuensch
Price Target
$155 -> $140
2026-01-23
New
downgrade
Buy
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on Abbott to $140 from $155 and keeps a Buy rating on the shares following the Q4 report. The firm believes Abbott will need post better quarters in order for the stock to regain momentum.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABT
Unlock Now
Bernstein
Outperform
to
NULL
downgrade
$154 -> $125
2026-01-23
New
Reason
Bernstein
Price Target
$154 -> $125
2026-01-23
New
downgrade
Outperform
to
NULL
Reason
Bernstein lowered the firm's price target on Abbott to $125 from $154 and keeps an Outperform rating on the shares. The firm notes the company's Q4 sales of $11.46B grew 3.0% organic and missed consensus by 3%. Nutrition declined 9% to $1.94B and missed by 12% or about $255M, which made up 75% of the $345M sales miss in the quarter.
Mizuho
Mizuho
Outperform -> Neutral
downgrade
$85 -> $105
2026-01-20
New
Reason
Mizuho
Mizuho
Price Target
$85 -> $105
2026-01-20
New
downgrade
Outperform -> Neutral
Reason
Mizuho downgraded Exact Sciences(EXAS) to Neutral from Outperform with a price target of $105, up from $85. The firm cites Abbott's (ABT) agreement to acquire Exact Sciences for $105 per share in cash for the downgrade. Mizuho sees minimal regulatory push-back to the deal and expects it to close on time by Q2.
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
